ArticleGHM open2024
The potential association between COVID-19 and Parkinson's disease-like symptoms.
Article in GHM open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the initial triggers of Parkinson's disease (PD) remain largely unknown, viral infections have been implicated in some cases. In this study, we investigated the neurological sequelae and explored the potential association between post COVID-19 conditions and the development of Parkinson's disease-like symptoms by conducting a questionnaire survey on patients with COVID-19. We surveyed patients who had recovered from COVID-19 and visited the outpatient service of the institution from February 2020 to November 2021. Demographic and clinical data and data regarding the presence and duration of post COVID-19 conditions were obtained. The most common symptom was insomnia, experienced by 141 participants (27.9%). Bradykinesia was the next most common symptom, experienced by 66 participants (13.1%). Moreover, 18 (3.6%) participants reported persistence for > 180 days. Notably, the median duration of bradykinesia was 90 days. The proportions of patients with dysbasia, resting tremor, not previously noted constipation, and somniloquy were 9.1%, 5.0%, 4.8%, and 2.8%, respectively. Few participants had any of these symptoms lasting for more than 180 days. None of the participants was first diagnosed with PD, other neurological diseases, or dementia after COVID-19. Longitudinal follow-up surveys are needed to better understand the relationship between COVID-19 and PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.